Takeda Pharmaceutical Co Ltd (NYSE:TAK)
| 17.71 Delayed Data As of 4:00pm ET |  +0.47 / +2.73%Today’s Change | 12.43 Today|||52-Week Range 20.00 | -2.69% Year-to-Date |
Latest TAK News | Press Releases
| Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold Mar 02 / Zacks.com - Paid Partner Content | The Top New Buys of Larry Robbins' Firm Feb 26 / GuruFocus News - Paid Partner Content |
| Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal Mar 01 / Zacks.com - Paid Partner Content | Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? Feb 19 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 17.24 |
| Today’s open | 17.67 |
| Day’s range | 17.53 - 17.79 |
| Volume | 5,169,356 |
| Average volume (3 months) | 2,869,777 |
| Market cap | $52.3B |
Data as of 4:00pm ET, 03/03/2021
Growth & Valuation
| Earnings growth (last year) | -74.46% |
| Earnings growth (this year) | +341.99% |
| Earnings growth (next 5 years) | +16.80% |
| Revenue growth (last year) | +60.06% |
| P/E ratio | 33.0 |
| Price/Sales | 1.57 |
| Price/Book | 1.19 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | -3.46 | -1.63% |
| ---- | ||
| REGNRegeneron Pharmaceut... | -8.25 | -1.81% |
| ---- |
Data as of 7:20pm ET, 03/03/2021
Financials
| Next reporting date | May 11, 2021 |
| EPS forecast (this quarter) | $0.33 |
| Annual revenue (last year) | $30.3B |
| Annual profit (last year) | $406.9M |
| Net profit margin | 1.34% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Osaka, Osaka |
Forecasts
